title: Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
abstract: Recently, there has been a renewed interest in the development of transmission-blocking vaccines (TBV) against Plasmodium falciparum malaria. While several candidate TBVs have been reported, studies directly comparing them in functional assays are limited. To this end, recombinant proteins of TBV candidates Pfs25, Pfs230, and PfHAP2 were expressed in the wheat germ cell-free expression system. Outbred CD-1 mice were immunized twice with the antigens. Two weeks after the second immunization, IgG levels were measured by enzyme-linked immunosorbent assay (ELISA), and IgG functionality was assessed by the standard membrane-feeding assay (SMFA) using cultured P. falciparum NF54 gametocytes and Anopheles stephensi mosquitoes. All three recombinant proteins elicited similar levels of antigen-specific IgG judged by ELISA. When IgGs purified from pools of immune serum were tested at 0.75 mg/ml in the SMFA, all three IgGs showed 97 to 100% inhibition in oocyst intensity compared to control IgG. In two additional independent SMFA evaluations, anti-Pfs25, anti-Pfs230, and anti-PfHAP2 IgGs inhibited oocyst intensity in a dose-dependent manner. When all three data sets were analyzed, anti-Pfs25 antibody showed significantly higher inhibition than the other two antibodies (P < 0.001 for both), while there was no significant difference between the other two (P = 0.15). A proportion of plasma samples collected from adults living in an area of malaria endemicity in Mali recognized Pfs230 and PfHAP2. This is the first study showing that the HAP2 protein of P. falciparum can induce transmission-blocking antibody. The current study supports the possibility of using this system for a comparative study with multiple TBV candidates.
authors.affiliation: Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
authors.forename: Kazutoyo
authors.initials: K
authors.lastname: Miura
authors.forename: Eizo
authors.initials: E
authors.lastname: Takashima
authors.forename: Bingbing
authors.initials: B
authors.lastname: Deng
authors.forename: Gregory
authors.initials: G
authors.lastname: Tullo
authors.forename: Ababacar
authors.initials: A
authors.lastname: Diouf
authors.forename: Samuel E
authors.initials: SE
authors.lastname: Moretz
authors.forename: Daria
authors.initials: D
authors.lastname: Nikolaeva
authors.forename: Mahamadou
authors.initials: M
authors.lastname: Diakite
authors.forename: Rick M
authors.initials: RM
authors.lastname: Fairhurst
authors.forename: Michael P
authors.initials: MP
authors.lastname: Fay
authors.forename: Carole A
authors.initials: CA
authors.lastname: Long
authors.forename: Takafumi
authors.initials: T
authors.lastname: Tsuboi
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000276:immunology; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission*; D051379:Mice; D010963:Plasmodium falciparum / Q000276:immunology; D015800:Protozoan Proteins / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D007074:Immunoglobulin G; D017780:Malaria Vaccines; C430263:Pfs230 antigen, Plasmodium falciparum; C071284:Pfs25 protein, Plasmodium falciparum; D015800:Protozoan Proteins; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic
references.citation: N Engl J Med. 2012 Dec 13;367(24):2284-95
references.pmid: 23136909
references.citation: Vaccine. 2005 May 2;23(24):3131-8
references.pmid: 15837212
references.citation: Infect Immun. 2008 Apr;76(4):1702-8
references.pmid: 18268027
references.citation: Nature. 1988 May 5;333(6168):74-6
references.pmid: 3283563
references.citation: Parasitology. 2007 Dec;134(Pt.14):1911-29
references.pmid: 17714601
references.citation: PLoS One. 2008 Jul 09;3(7):e2636
references.pmid: 18612426
references.citation: Acta Trop. 2010 Jun;114(3):171-6
references.pmid: 19913490
references.citation: Vaccine. 2012 Mar 2;30(11):1972-80
references.pmid: 22248820
references.citation: Vaccine. 2009 Aug 20;27(38):5187-94
references.pmid: 19596419
references.citation: Mol Biochem Parasitol. 1995 Dec;75(1):33-42
references.pmid: 8720173
references.citation: PLoS One. 2013;8(3):e57909
references.pmid: 23483940
references.citation: Vaccine. 2008 Jan 10;26(2):193-200
references.pmid: 18054414
references.citation: PLoS Med. 2011 Jan 25;8(1):e1000398
references.pmid: 21311586
references.citation: Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13461-6
references.pmid: 17673553
references.citation: Clin Vaccine Immunol. 2011 Aug;18(8):1343-50
references.pmid: 21715579
references.citation: Lancet. 2012 Feb 4;379(9814):413-31
references.pmid: 22305225
references.citation: Malar J. 2011 Jul 14;10:192
references.pmid: 21756349
references.citation: Infect Immun. 2011 Nov;79(11):4523-32
references.pmid: 21896773
references.citation: J Biol Chem. 2010 Aug 6;285(32):24855-62
references.pmid: 20529864
references.citation: PLoS One. 2009 Jul 22;4(7):e6352
references.pmid: 19623257